

KEY TAKEAWAYS

The largest U.S. Medicare and commercial claims analysis of four BPH procedures reveals:

300 days post-treatment

- Overall complication rates are lowest after UroLift® System PUL: 16.3% for the UroLift System PUL; 19.7% for TURP; 21.6% for GreenLight PVP; and 23.0% for Rezūm™ WVT

4 years post-treatment

- Surgical retreatment rates are comparable among UroLift System PUL (6.8%), TURP (6.3%) and GreenLight PVP (7.0%), and are highest after Rezūm WVT (9.5%)




REASON FOR THE STUDY

- Real-world data can provide additional perspective in the debate about how new BPH therapies compare to each other and traditional surgeries
- Retreatment and complication rates are at the center of the debate, but it is difficult to compare controlled trials with significant differences in concept and execution
- A large-scale analysis of healthcare claims can provide a foundation to compare event rates following treatment

AIM OF THE STUDY

To evaluate rates of surgical retreatment and post-operative complications endured by patients who underwent TURP, GreenLight Photoselective Vaporization (PVP), UroLift System Prostatic Urethral Lift (PUL), or Rezūm Water Vapor Therapy (WVT).



METHOD


- Patient-level longitudinal, observational analysis of a representative sample of U.S. Medicare and commercial outpatient claims obtained from IBM Watson from 2015 to 2019
- Included in the database were men with BPH diagnoses who underwent TURP, GreenLight PVP, UroLift System PUL, or Rezūm WVT
- Average age at index: 64 Rezūm WVT, 65 UroLift System PUL, and 67 GreenLight PVP and TURP
- Analysis of event rates includes:

Surgical retreatment: A second BPH procedure (Rezūm WVT, GreenLight PVP, TURP, UroLift System PUL or HoLEP) subsequent to index procedure

Complication: A post-operative procedure performed during a return visit to an outpatient setting subsequent to index procedure


OVERALL RATE OF COMPLICATIONS IS LOWEST AFTER UROLIFT® SYSTEM PUL

Cumulative Incidence of Complications After UroLift® System PUL, Rezūm WVT, GreenLight PVP, and TURP through 365 days



RATE OF SURGICAL RETREATMENT IS HIGHEST AFTER REZŪM WVT

Cumulative Incidence of Surgical Retreatment After UroLift System PUL, Rezūm WVT, GreenLight PVP, and TURP through 1,500 days



Indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 50 years or older. As with any medical procedure, individual results may vary. Most common side effects are temporary and include dysuria, hematuria, pelvic pain, micturition urgency, urge incontinence (Roehrborn, J Urology 2013). Rare side effects, including bleeding and infection, may lead to a serious outcome and may require intervention. Consult indications approved for your geography and the Instructions for Use (IFU) for more information. ifu.teleflex.com

Not all products may be available in all countries. For product information please contact la.cs@teleflex.com or your local representative. Please check your local regulatory approval status.

BPH Relief. In Sight. UroLift, the UroLift logo, NeoTract, the NeoTract logo, Teleflex and the Teleflex logo are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries. ©2021 Teleflex Incorporated. All rights reserved. Revised: 08/2021. MC-007542 LA EN